Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gwin

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal for Immunotherapy of Cancer|May 4, 2026
Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancerSasha E Stanton, Denise L Cecil, Howard H Bailey, et al.
Journal for Immunotherapy of Cancer|September 17, 2021
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlatesJohn B Liao, William R Gwin, Renata R Urban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 TrialHope S Rugo, Seock-Ah Im, Fatima Cardoso, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal for Immunotherapy of Cancer|May 4, 2026
Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancerSasha E Stanton, Denise L Cecil, Howard H Bailey, et al.
Journal for Immunotherapy of Cancer|September 17, 2021
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlatesJohn B Liao, William R Gwin, Renata R Urban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 TrialHope S Rugo, Seock-Ah Im, Fatima Cardoso, et al.
Pageof 3